We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add CLOV Stock to Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
CLOV Medicare Advantage membership rose 32% to 106K, driving Q2 insurance revenues up 34% to $470M.
CLOV's AI Assistant improved COPD outcomes, cutting hospitalizations 15% and readmissions 18% for patients.
CLOV posted $43M adjusted EBITDA in 1H 2025 and raised full-year guidance to $50-$70M profitability.
Clover Health Investments (CLOV - Free Report) is well poised for growth in the coming quarters, courtesy of its broad product spectrum. The optimism, led by the solid membership growth, rising revenues, and sustained adjusted EBITDA profitability, was powered by its technology-first care model. However, elevated medical costs, IRA-related Part D uncertainties and execution risks in scaling Clover Assistant present near-term challenges.
Shares of this Zacks Rank #2 (Buy) company have lost 16.8% so far this year against the industry’s 25.8% gain. The S&P 500 Index has increased 10.1% in the same time frame.
Clover Health, a tech-enabled Medicare Advantage insurer leveraging its proprietary AI-powered platform, has a market capitalization of $1.38 billion. The company projects 200% earnings growth for the third quarter of 2025 and expects to maintain its strong performance going forward.
Image Source: Zacks Investment Research
Its earnings surpassed estimates in three of the trailing four quarters and met once, delivering an average surprise of 83.33%.
Factors Favoring CLOV Stock
Membership and Revenue Growth: Clover reported a robust 32% year-over-year increase in Medicare Advantage membership, reaching more than 106,000 members, and a 34% rise in insurance revenues to $470 million for the second quarter. This momentum places the company well above industry growth averages. Clover emphasizes retention and quality of cohorts, expecting improved economics as new members mature into returning ones. With a 4-star payment year ahead in 2026, this growth trajectory provides both scale and financial tailwinds, enhancing the company’s ability to invest further in affordability and quality initiatives.
Differentiated Technology-First Model: At the heart of Clover’s strategy is its Clover Assistant (CA) platform, which drives early disease detection and care coordination. Clinical data show CA-linked providers delivered 15% fewer hospitalizations and 18% fewer re-admissions in COPD patients, underscoring measurable healthcare outcomes. The company also continues to expand CA’s reach beyond its own plan to health systems, ACOs and pharmacies. This ecosystem approach not only strengthens Clover’s core business but also creates additional revenue opportunities. With CMS pushing interoperability and data sharing, Clover’s AI-driven model is well-positioned to benefit from federal policy tailwinds.
Path to Sustained Profitability: In the first half of 2025, Clover achieved adjusted EBITDA profitability of $43 million and reduced its net loss to $12 million.Importantly, adjusted SG&A was 17% of revenues, down 280 basis points year over year, reflecting strong operating leverage despite significant membership growth. Management remains confident in maintaining $50-$70 million adjusted EBITDA for 2025 and sees stronger profitability in 2026, aided by star rating upgrades and operating efficiencies. This combination of scale, cost control, and improved quality metrics strengthens investor confidence in Clover’s ability to balance growth with profitability.
Key Challenges
Rising Medical Cost Trends and Part D Uncertainty: Despite strong growth, Clover faces headwinds from elevated Medicare Advantage cost trends, particularly in Part D drug utilization under the IRA’s new framework and supplemental benefits like dental. The insurance benefit expense ratio (BER) rose year over year to 88.4% from 76.1%, leading management to raise full-year BER guidance to 88.5-89.5%. While BER may decline in 2026, near-term variability in drug costs remains a significant risk that could pressure margins and test Clover’s cost-management model.
Competitive Pressures in Medicare Advantage: National insurers are scaling back PPO offerings due to cost challenges, but this may benefit as well as hurt Clover’s prospects. While it opens growth opportunities, it also means heightened competition in pricing and retention within core markets. Clover’s wide-network PPO strategy is differentiated but requires careful execution to sustain risks while managing utilization. Meanwhile, rising competition and aggressive repricing of products by rivals may pose challenges for Clover’s membership growth and profitability.
Estimate Trend
Clover is witnessing a declining estimate revision trend for 2025. In the past 30 days, the Zacks Consensus Estimate for earnings has moved south 1 cent to 10 cents per share.
The Zacks Consensus Estimate for third-quarter 2025 revenues and EPS is pegged at $475.4 million and 2 cents, respectively.
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Medpace Holdings, currently sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, which outpaced the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Add CLOV Stock to Your Portfolio Now
Key Takeaways
Clover Health Investments (CLOV - Free Report) is well poised for growth in the coming quarters, courtesy of its broad product spectrum. The optimism, led by the solid membership growth, rising revenues, and sustained adjusted EBITDA profitability, was powered by its technology-first care model. However, elevated medical costs, IRA-related Part D uncertainties and execution risks in scaling Clover Assistant present near-term challenges.
Shares of this Zacks Rank #2 (Buy) company have lost 16.8% so far this year against the industry’s 25.8% gain. The S&P 500 Index has increased 10.1% in the same time frame.
Clover Health, a tech-enabled Medicare Advantage insurer leveraging its proprietary AI-powered platform, has a market capitalization of $1.38 billion. The company projects 200% earnings growth for the third quarter of 2025 and expects to maintain its strong performance going forward.
Image Source: Zacks Investment Research
Its earnings surpassed estimates in three of the trailing four quarters and met once, delivering an average surprise of 83.33%.
Factors Favoring CLOV Stock
Membership and Revenue Growth: Clover reported a robust 32% year-over-year increase in Medicare Advantage membership, reaching more than 106,000 members, and a 34% rise in insurance revenues to $470 million for the second quarter. This momentum places the company well above industry growth averages. Clover emphasizes retention and quality of cohorts, expecting improved economics as new members mature into returning ones. With a 4-star payment year ahead in 2026, this growth trajectory provides both scale and financial tailwinds, enhancing the company’s ability to invest further in affordability and quality initiatives.
Differentiated Technology-First Model: At the heart of Clover’s strategy is its Clover Assistant (CA) platform, which drives early disease detection and care coordination. Clinical data show CA-linked providers delivered 15% fewer hospitalizations and 18% fewer re-admissions in COPD patients, underscoring measurable healthcare outcomes. The company also continues to expand CA’s reach beyond its own plan to health systems, ACOs and pharmacies. This ecosystem approach not only strengthens Clover’s core business but also creates additional revenue opportunities. With CMS pushing interoperability and data sharing, Clover’s AI-driven model is well-positioned to benefit from federal policy tailwinds.
Path to Sustained Profitability: In the first half of 2025, Clover achieved adjusted EBITDA profitability of $43 million and reduced its net loss to $12 million.Importantly, adjusted SG&A was 17% of revenues, down 280 basis points year over year, reflecting strong operating leverage despite significant membership growth. Management remains confident in maintaining $50-$70 million adjusted EBITDA for 2025 and sees stronger profitability in 2026, aided by star rating upgrades and operating efficiencies. This combination of scale, cost control, and improved quality metrics strengthens investor confidence in Clover’s ability to balance growth with profitability.
Key Challenges
Rising Medical Cost Trends and Part D Uncertainty: Despite strong growth, Clover faces headwinds from elevated Medicare Advantage cost trends, particularly in Part D drug utilization under the IRA’s new framework and supplemental benefits like dental. The insurance benefit expense ratio (BER) rose year over year to 88.4% from 76.1%, leading management to raise full-year BER guidance to 88.5-89.5%. While BER may decline in 2026, near-term variability in drug costs remains a significant risk that could pressure margins and test Clover’s cost-management model.
Competitive Pressures in Medicare Advantage: National insurers are scaling back PPO offerings due to cost challenges, but this may benefit as well as hurt Clover’s prospects. While it opens growth opportunities, it also means heightened competition in pricing and retention within core markets. Clover’s wide-network PPO strategy is differentiated but requires careful execution to sustain risks while managing utilization. Meanwhile, rising competition and aggressive repricing of products by rivals may pose challenges for Clover’s membership growth and profitability.
Estimate Trend
Clover is witnessing a declining estimate revision trend for 2025. In the past 30 days, the Zacks Consensus Estimate for earnings has moved south 1 cent to 10 cents per share.
The Zacks Consensus Estimate for third-quarter 2025 revenues and EPS is pegged at $475.4 million and 2 cents, respectively.
Clover Health Investments, Corp. Price
Clover Health Investments, Corp. price | Clover Health Investments, Corp. Quote
Other Stocks to Consider
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Medpace Holdings, currently sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, which outpaced the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.